Ask AI
ProCE Banner Activity

Exploring Future Roles for Immune-Oncology in Head and Neck Cancer: Slides

Slideset Download
Downloadable slides review current clinical trials with immunotherapies for patients with advanced metastatic head and neck cancer.

Released: January 05, 2021

Expiration: January 04, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Chief Translational Officer
Associate Director, Translational Research
Chief, Head and Neck/Sarcoma Oncology
Co-Leader, Developmental Therapeutics Program
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Barbara Burtness, MD, has disclosed that she has received consulting fees from Aduro, ALX Oncology, Celgene, Chemotherapy Advisory, Cue Biopharma, Debio Pharm, GlaxoSmithKline, IO Biotech, Kura, MacroGenics, Maverick, Merck, Nanobiotix, and Rakuten.